The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Official Title: A Phase II Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Study ID: NCT00699296
Brief Summary: This study will assess the safety, efficacy and pharmacokinetics of oral LBH589 in Japanese adult patients with refractory cutaneous T-Cell Lymphoma and adult T-cell leukemia/lymphoma. LBH589 is administered orally once a day for three days per week.
Detailed Description:
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University Hospital of Occupational and Environmental Health, Fukuoka, , Japan
Imamura Bun-in Hospital, Kagoshima, , Japan
Kumamoto University Hospital, Kumamoto, , Japan
University of Miyazaki Hospital, Miyazaki, , Japan
Nagasaki University Hospital of Medicine and Dentistry, Nagasaki, , Japan
Okayama University Hospital, Okayama, , Japan
The University of Tokyo Hospital, Tokyo, , Japan
Name: Makoto Sugaya
Affiliation: The University of Tokyo Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Kenji Iwatsuki
Affiliation: Okayama University
Role: PRINCIPAL_INVESTIGATOR
Name: Yoshiki Tokura
Affiliation: University Hospital of Occupational and Environmental Health
Role: PRINCIPAL_INVESTIGATOR
Name: Kunihiro Tsukasaki
Affiliation: Nagasaki University Hospital of Medicine and Dentistry
Role: PRINCIPAL_INVESTIGATOR
Name: Hironobu In
Affiliation: Kumamoto University Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Mitsuru Setoyama
Affiliation: University of Miyazaki Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Atae Utsunomiya
Affiliation: Imamura Bun-in Hospital
Role: PRINCIPAL_INVESTIGATOR